# Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

> **NCT05190991** · PHASE2 · RECRUITING · sponsor: **R-Pharm International, LLC** · enrollment: 60 (estimated)

## Conditions studied

- Familial Mediterranean Fever
- FMF

## Interventions

- **BIOLOGICAL:** RPH-104

## Key facts

- **NCT ID:** NCT05190991
- **Lead sponsor:** R-Pharm International, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-05
- **Primary completion:** 2028-12
- **Final completion:** 2029-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-12-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05190991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05190991, "Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05190991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*